Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015)

Abstract

Activities of tedizolid and comparators were evaluated against gram-positive isolates responsible for skin and skin structure infections, pneumonia, and bloodstream infections. Non-duplicate gram-positive isolates (8011) were collected from 20 European countries/regions. Tedizolid (0.12 mg/L) showed similar results of minimum inhibitory concentration required to inhibit the growth of 50% of organisms (MIC₅₀) regardless of pathogen/group or infection type, except for coagulase-negative staphylococci, Enterococcus faecalis, and viridans group streptococci (VGS), against which tedizolid had MIC₅₀ values of 0.06, 0.25, and 0.06 mg/L, respectively. Similar results of tedizolid MIC₅₀ and minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC₉₀) (MIC_50/90, 0.12/0.12 mg/L) were obtained against methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Tedizolid, linezolid, and daptomycin were active against enterococci. Tedizolid (MIC₉₀, 0.12-0.25 mg/L), ceftaroline (MIC₉₀, 0.12 mg/L), and vancomycin (MIC₉₀, 0.25-0.5 mg/L) had the lowest MIC₉₀ values against Streptococcus pneumoniae and VGS, whereas ceftaroline (MIC₉₀, ≤0.015 mg/L), penicillin (MIC₉₀, ≤0.06 mg/L), ceftriaxone (MIC₉₀, ≤0.06-0.12 mg/L), and tedizolid (MIC₉₀, 0.12 mg/L) were the most potent against β-haemolytic streptococci. Tedizolid displayed potent activity against gram-positive isolates from Europe, regardless of infection type.

Keywords: Disease; Linezolid; MRSA; Oxazolidinones; Surveillance; VRE.